Influence of Chinese herbal medicine Feitai Capsule on completion or delay of chemotherapy in patients with stage ⅢB/Ⅳ non-small-cell lung cancer: a randomized controlled trial
| Autor: | Xi Chen, Zong-Yang Yu, Xue-Nong Ouyang, Xi-hu Dai, Shui-qiu Deng, Zhizhen Liu, Wen-Wu Wang, Fang-zheng Fang |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty Lung Neoplasms medicine.medical_treatment Capsules Traditional Chinese medicine law.invention Treatment and control groups Randomized controlled trial law Carcinoma Non-Small-Cell Lung Internal medicine Antineoplastic Combined Chemotherapy Protocols Humans Medicine In patient Lung cancer Aged Neoplasm Staging Chemotherapy business.industry Capsule Middle Aged Stage iiib medicine.disease Surgery Treatment Outcome Complementary and alternative medicine Female business Drugs Chinese Herbal Phytotherapy |
| Zdroj: | Journal of Chinese Integrative Medicine. 10:635-640 |
| ISSN: | 1672-1977 |
| DOI: | 10.3736/jcim20120606 |
| Popis: | BACKGROUND Chemotherapy completion rate can reflect the tolerance and compliance of patients to chemotherapy. Poor tolerance may result in delay or suspension of the comprehensive treatment plan, thus affect the efficacy of cancer treatment. Evaluating methods to improve the completion rate of chemotherapy and reduce the occurrence of delayed chemotherapy has gained increasing attention and is the significant area of study in the field of cancer treatment. Studies have shown that Chinese medicine combined with chemotherapy could improve the quality of life in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC). OBJECTIVE To observe the effects of Feitai Capsule, a Chinese patent herbal drug, combined with chemotherapy in patients with stage IIIB/IV NSCLC. DESIGN, SETTING, PARTICIPANTS AND INTERVENTIONS A total of 60 diagnosed stage IIIB/IV NSCLC patients from the Department of Oncology, Fuzhou General Hosipital of Najing Military Region were randomly divided into treatment group (30 cases) and control group (30 cases). Patients in the treatment group were treated with chemotherapy plus Feitai Capsule and patients in the control group only received chemotherapy. Both groups of patients were treated for 4 therapeutic cycles. MAIN OUTCOME MEASURES The chemotherapy completion rate and the chemotherapy delay rate were observed in each cycle of treatment. The therapeutic efficacy was evaluated after 4 cycles. RESULTS The chemotherapy completion rate was 96.42% in the treatment group, while that of the control group was 74.07%. The chemotherapy delay rate was 3.57% in the treatment group, while that of the control group was 14.8% (P=0.007 0). The disease control rate was 78.6% in the treatment group, while that of the control group was 59.3% (P=0.173 9). CONCLUSION Feitai Capsule can increase the chemotherapy completion rate in patients with stage IIIB/IV NSCLC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|